Chemotherapy and anti-CD20 monoclonal antibody impact on SARS-CoV-2 nucleic acid amplification tests in hematologic malignancies: a retrospective study
The use of anti-CD20 mAbs, especially obinutuzumab and maintenance treatment, is associated with long-term SARS-CoV-2 infection in patients with hematologic malignancies.
Authors
- Ryuichi Minoda Sada (ORCID: https://orcid.org/0000-0002-1455-6822)
- Hirofumi Miyake (ORCID: https://orcid.org/0000-0001-5655-6356)
- Keiichiro Kinoshita
- W. Maruyama (ORCID: https://orcid.org/0000-0003-4546-379X)
Institutions
- Tenri Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1186/s12879-025-11844-z
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00